[Questionable efficacy and safety of activated drotrecogin alpha (activated protein C) in the treatment of severe sepsis].
Girbes
A R J
AR
Polderman
K H
KH
Beishuizen
A
A
van Zanten
A R H
AR
Schultz
M J
MJ
D000890:Anti-Infective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003257:Consumer Product Safety; D006801:Humans; D017410:Practice Guidelines as Topic; D011486:Protein C / Q000009:adverse effects* / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D018805:Sepsis / Q000188:drug therapy* / Q000401:mortality; D016896:Treatment Outcome
D000890:Anti-Infective Agents; D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated